Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels In Vivo and Correlation to In Vitro Potency in Primary Cortical Neurons from Mouse and Guinea Pig
- 648 Downloads
The aims were to quantify the in vivo time-course between the oral dose, the plasma and brain exposure and the inhibitory effect on Amyloid β (Aβ) in brain and cerebrospinal fluid, and to establish the correlation between in vitro and in vivo potency of novel β-secretase (BACE1) inhibitors.
BACE1-mediated inhibition of Aβ was quantified in in vivo dose- and/or time-response studies and in vitro in SH-SY5Y cells, N2A cells, and primary cortical neurons (PCN). An indirect response model with inhibition on Aβ production rate was used to estimate unbound in vivo IC 50 in a population pharmacokinetic-pharmacodynamic modeling approach.
Estimated in vivo inhibitory potencies varied between 1 and 1,000 nM. The turnover half-life of Aβ40 in brain was predicted to be 0.5 h in mouse and 1 h in guinea pig. An excellent correlation between PCN and in vivo potency was observed. Moreover, a strong correlation in potency was found between human SH-SY5Y cells and mouse PCN, being 4.5-fold larger in SH-SY5Y cells.
The strong in vivo-in vitro correlation increased the confidence in using human cell lines for screening and optimization of BACE1 inhibitors. This can optimize the design and reduce the number of preclinical in vivo effect studies.
KEY WORDSAlzheimer’s disease amyloid β peptide brain cerebrospinal fluid pharmacokinetic-pharmacodynamic modeling
Amyloid precursor protein
Amyloid β peptide
β-site APP-cleaving enzyme 1
Coefficient of variation
Primary cortical neurons
Soluble N terminal fragment of APP
ACKNOWLEDGMENTS AND DISCLOSURES
The authors would like to thank Eva Spennare for determining the fraction unbound in brain; Jenny Johansson for measuring the plasma protein binding; Hongmei Yan for collecting the data into the data-analysis sheet; Sveinn Briem and his team for performing the bioanalysis; Elin Lundkvist and Fredrik Olsson for supporting the in vitro experiments; and Kristina Eliason for supporting the in vivo experiments.
- 1.McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.PubMedCrossRefGoogle Scholar
- 16.Niva C, Parkinson J, Olsson F, van Schaick EA, Lundkvist J, Visser SAG. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data. Eur J Clin Pharmacol. 2013. doi: 10.1007/s00228-012-1459-3.PubMedGoogle Scholar
- 30.Lu Y, Zhang L, Nolan CE, Becker SL, Atchison K, Robshaw AE, et al. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule gamma-secretase inhibitors. J Pharmacol Exp Ther. 2011;339(3):922–34.PubMedCrossRefGoogle Scholar
- 35.Lu Y, Riddell D, Hajos-Korcsok E, Bales K, Wood KM, Nolan CE, et al. CSF Aβ As An Effect Biomarker For Brain Aβ Lowering Verified by Quantitative Preclinical Analyses. J Pharmacol Exp Ther. 2012;342(2):366–75.Google Scholar
- 36.Rueeger H, Lueoend R, Rogel O, Rondeau JM, Mobitz H, Machauer R, et al. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. J Med Chem. 2012;55(7):3364–86.PubMedCrossRefGoogle Scholar
- 37.Wood S, Wen PH, Zhang J, Zhu L, Luo Y, Babu-Khan S, et al. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors. J Pharmacol Exp Ther. 2012;343(2):460–7.PubMedCrossRefGoogle Scholar
- 41.Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, et al. First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2009;328(1):131–40.PubMedCrossRefGoogle Scholar
- 47.Borgegård T, Minidis A, Jureus A, Malmborg J, Rosqvist S, Gruber, S., Almqvist, H., et al. In vivo analysis using a presenilin-1-specific inhibitor: Presenilin 1- containing g-secretase complexes mediate the majority of CNS Ab production in the mouse. 3 2011;1:30–45.Google Scholar
- 51.Liu L, Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp 2008 Nov 10;(21).Google Scholar
- 53.Lu Y. Integrating experimentation and quantitative modeling to enhance discovery of Beta amyloid lowering therapeutics for Alzheimer’s disease. Front Pharmacol. 2012;3(177):1–6.Google Scholar
- 54.Danhof M, Van der Graaf PH, Jonker DM, Visser SAG, Zuideveld KP. Mechanism-based pharmacokinetic-pharmacodynamic modeling for the prediction of in vivo drug concentration-effect relationships -application in drug candidate selection and lead optimization. 2007. Comprehensive Medicinal Chemistry (2nd Ed.) Volume 5: “ADME-Tox: The Fate of Drugs in the Body”. Editors Bernard Testa and Han van de Waterbeemd.Google Scholar